Serum sodium, renal function, and survival of patients with end-stage liver disease

Journal of Hepatology

Volumn 52, Issue 4, 2010, Pages 523-528

  Lim, Young Suk ^a   Larson, Timothy S ^b   Benson, Joanne T ^b   Kamath, Patrick S ^a   Kremers, Walter K ^b   Therneau, Terry M ^b   Kim, W Ray ^a  

^a MAYO CLINIC   (United States)

^b Mayo Clinic College of Medicine   (United States)

Author keywords

Glomerular filtration rate; Liver cirrhosis; MELD; Prognosis

Indexed keywords

BILIRUBIN; CREATININE; IOTALAMIC ACID I 125; SODIUM;

ADOLESCENT; ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; LIVER DISEASE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SODIUM BLOOD LEVEL; SURVIVAL;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CREATININE; DATABASES, FACTUAL; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SODIUM; SURVIVAL ANALYSIS; WAITING LISTS; YOUNG ADULT;

EID: 77949654357     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.01.009     Document Type: Article

References (40)

1. Kamath P.S., Wiesner R.H., Malinchoc M., Kremers W., Therneau T.M., Kosberg C.L., et al. A model to predict survival in patients with end-stage liver disease. Hepatology 33 (2001) 464-470
2. Freeman Jr. R.B., Wiesner R.H., Harper A., McDiarmid S.V., Lake J., Edwards E., et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 8 (2002) 851-858
3. Wiesner R., Edwards E., Freeman R., Harper A., Kim R., Kamath P., et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 124 (2003) 91-96
4. Kamath P.S., and Kim W.R. The model for end-stage liver disease (MELD). Hepatology 45 (2007) 797-805
5. Wiesner R.H. Evidence-based evolution of the MELD/PELD liver allocation policy. Liver Transpl 11 (2005) 261-263
6. Heuman D.M., Abou-Assi S.G., Habib A., Williams L.M., Stravitz R.T., Sanyal A.J., et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 40 (2004) 802-810
7. Biggins S.W., Rodriguez H.J., Bacchetti P., Bass N.M., Roberts J.P., and Terrault N.A. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 41 (2005) 32-39
8. Ruf A.E., Kremers W.K., Chavez L.L., Descalzi V.I., Podesta L.G., and Villamil F.G. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 11 (2005) 336-343
9. Londono M.C., Cardenas A., Guevara M., Quinto L., de Las Heras D., Navasa M., et al. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut 56 (2007) 1283-1290
10. Kim W.R., Biggins S.W., Kremers W.K., Wiesner R.H., Kamath P.S., Benson J.T., et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 359 (2008) 1018-1026
11. Sherlock S., Senewiratne B., Scott A., and Walker J.G. Complications of diuretic therapy in hepatic cirrhosis. Lancet 1 (1966) 1049-1052
12. Llach J., Gines P., Arroyo V., Rimola A., Tito L., Badalamenti S., et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 94 (1988) 482-487
13. Davis C.L., Gonwa T.A., and Wilkinson A.H. Pathophysiology of renal disease associated with liver disorders: implications for liver transplantation. Part I. Liver Transpl 8 (2002) 91-109
14. Cooper G.S., Bellamy P., Dawson N.V., Desbiens N., Fulkerson Jr. W.J., Goldman L., et al. A prognostic model for patients with end-stage liver disease. Gastroenterology 113 (1997) 1278-1288
15. Caregaro L., Menon F., Angeli P., Amodio P., Merkel C., Bortoluzzi A., et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med 154 (1994) 201-205
16. Thomas L., and Huber A.R. Renal function - estimation of glomerular filtration rate. Clin Chem Lab Med 44 (2006) 1295-1302
17. Gonwa T.A., Jennings L., Mai M.L., Stark P.C., Levey A.S., and Klintmalm G.B. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver transpl 10 (2004) 301-309
18. Sansoe G., Silvano S., Mengozzi G., Todros L., Smedile A., Touscoz G., et al. Inappropriately low angiotensin II generation: a factor determining reduced kidney function and survival in patients with decompensated cirrhosis. J Hepatol 40 (2004) 417-423
19. Sherman D.S., Fish D.N., and Teitelbaum I. Assessing renal function in cirrhotic patients: problems and pitfalls. Am J Kidney Dis 41 (2003) 269-278
20. Giles P.D., and Fitzmaurice D.A. Formula estimation of glomerular filtration rate: have we gone wrong?. BMJ 334 (2007) 1198-1200
21. Freeman R.B., Wiesner R.H., Edwards E., Harper A., Merion R., and Wolfe R. Results of the first year of the new liver allocation plan. Liver Transpl 10 (2004) 7-15
22. Ott N.T. A simple technique for estimating glomerular filtration rate with subcutaneous injection of (125I)lothalamate. Mayo Clin Proc 50 (1975) 664-668
23. Wilson D.M., Bergert J.H., Larson T.S., and Liedtke R.R. GFR determined by nonradiolabeled iothalamate using capillary electrophoresis. Am J Kidney Dis 30 (1997) 646-652
24. Rule A.D., Gussak H.M., Pond G.R., Bergstralh E.J., Stegall M.D., Cosio F.G., et al. Measured and estimated GFR in healthy potential kidney donors. Am J Kidney Dis 43 (2004) 112-119
25. Cohen A.J., Stegall M.D., Rosen C.B., Wiesner R.H., Leung N., Kremers W.K., et al. Chronic renal dysfunction late after liver transplantation. Liver transpl 8 (2002) 916-921
26. Kim W.R., Therneau T.M., Benson J.T., Kremers W.K., Rosen C.B., Gores G.J., et al. Deaths on the liver transplant waiting list: an analysis of competing risks. Hepatology 43 (2006) 345-351
27. Levey A.S., Coresh J., Greene T., Stevens L.A., Zhang Y.L., Hendriksen S., et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145 (2006) 247-254
28. Gines A., Escorsell A., Gines P., Salo J., Jimenez W., Inglada L., et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 105 (1993) 229-236
29. Gines P., Martin P.Y., and Niederberger M. Prognostic significance of renal dysfunction in cirrhosis. Kidney Int Suppl 61 (1997) S77-S82
30. Fernandez-Esparrach G., Sanchez-Fueyo A., Gines P., Uriz J., Quinto L., Ventura P.J., et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 34 (2001) 46-52
31. Sort P., Navasa M., Arroyo V., Aldeguer X., Planas R., Ruiz-del-Arbol L., et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 341 (1999) 403-409
32. Hecker R., and Sherlock S. Electrolyte and circulatory changes in terminal liver failure. Lancet 271 (1956) 1121-1125
33. Cardenas A., Gines P., Uriz J., Bessa X., Salmeron J.M., Mas A., et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. Hepatology 34 (2001) 671-676
34. Roy L., Legault L., and Pomier-Layrargues G. Glomerular filtration rate measurement in cirrhotic patients with renal failure. Clin Nephrol 50 (1998) 342-346
35. Cocchetto D.M., Tschanz C., and Bjornsson T.D. Decreased rate of creatinine production in patients with hepatic disease: implications for estimation of creatinine clearance. Ther Drug Monit 5 (1983) 161-168
36. Takabatake T., Ohta H., Ishida Y., Hara H., Ushiogi Y., and Hattori N. Low serum creatinine levels in severe hepatic disease. Arch Intern Med 148 (1988) 1313-1315
37. Gecelter G.R., and Comer G.M. Nutritional support during liver failure. Crit Care Clin 11 (1995) 675-683
38. Biggins S.W., Kim W.R., Terrault N.A., Saab S., Balan V., Schiano T., et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 130 (2006) 1652-1660
39. Gines P., Wong F., Watson H., Milutinovic S., del Arbol L.R., and Olteanu D. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology 48 (2008) 204-213
40. Schrier R.W., Gross P., Gheorghiade M., Berl T., Verbalis J.G., Czerwiec F.S., et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355 (2006) 2099-2112